The biology of chronic myeloid leukemia.

PubWeight™: 4.80‹?› | Rank: Top 1%

🔗 View Article (PMID 10403855)

Published in N Engl J Med on July 15, 1999

Authors

S Faderl1, M Talpaz, Z Estrov, S O'Brien, R Kurzrock, H M Kantarjian

Author Affiliations

1: Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Associated clinical trials:

TIGIT in Patients With Chronic Myeloid Leukemia | NCT04818619

Articles citing this

(truncated to the top 100)

Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15

Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76

Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Cell (2007) 2.61

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood (2012) 2.46

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood (2009) 2.29

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood (2012) 2.11

Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A (2000) 1.69

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer (2010) 1.64

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag (2008) 1.59

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res (2008) 1.45

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood (2008) 1.44

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood (2008) 1.25

Drug repositioning for personalized medicine. Genome Med (2012) 1.24

The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood (2009) 1.23

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia (2008) 1.21

Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia (2008) 1.20

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica (2014) 1.17

The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol (2003) 1.14

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood (2007) 1.14

An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism. J Clin Invest (2005) 1.14

FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol (2001) 1.12

Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation (2009) 1.11

Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood (2005) 1.10

Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A (2000) 1.09

Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem (2010) 1.08

Synaptic plasticity, a symphony in GEF. ACS Chem Neurosci (2010) 1.06

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer (2010) 1.02

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res (2007) 1.02

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol (2014) 1.01

A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One (2010) 1.00

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest (2012) 0.99

Oncohematological diseases in the Vale do Paraíba, State of São Paulo: demographic aspects, prevalences and incidences. Rev Bras Hematol Hemoter (2011) 0.98

The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica (2016) 0.97

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med (2014) 0.97

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med (2013) 0.96

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol (2008) 0.95

TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest (2004) 0.95

The kinetics of clonal dominance in myeloproliferative disorders. Blood (2005) 0.93

Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel) (2010) 0.92

Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther (2009) 0.91

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. PLoS One (2013) 0.91

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol (2013) 0.90

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One (2009) 0.90

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood (2016) 0.90

Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy. Adv Hematol (2010) 0.89

Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment. J Med Life (2010) 0.89

Primary hyperparathyroidism in a case of chronic myelogenous leukemia. Indian J Endocrinol Metab (2013) 0.88

NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw (2011) 0.88

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica (2010) 0.88

Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Blood Disord (2010) 0.87

A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells. Mol Cancer Ther (2010) 0.87

Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology (2012) 0.87

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med (2009) 0.86

p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica (2011) 0.85

Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia. Adv Hematol (2009) 0.85

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther (2009) 0.85

New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol (2009) 0.84

Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors. Leuk Lymphoma (2009) 0.84

Recommendations of the canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol (2006) 0.84

Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras. Mol Cell Biol (2006) 0.83

Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J (2009) 0.83

Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth. DNA Cell Biol (2010) 0.83

Effector caspases and leukemia. Int J Cell Biol (2011) 0.83

BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer (2006) 0.83

BCR-ABL affects STAT5A and STAT5B differentially. PLoS One (2014) 0.83

Chronic Myeloid Leukemia: A Case of Extreme Thrombocytosis Causing Syncope and Myocardial Infarction. Cureus (2016) 0.83

An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J Fam Med (2015) 0.83

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer (2002) 0.82

Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements. Proc Natl Acad Sci U S A (2013) 0.82

Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples. J Mol Diagn (2013) 0.82

Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report. Case Rep Oncol (2010) 0.81

Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol (2006) 0.81

Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias. PLoS One (2014) 0.81

Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia. Bioinformation (2014) 0.81

Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet Vaccines Ther (2008) 0.80

Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia. Pharmgenomics Pers Med (2013) 0.80

Organopalladium compound 7b targets mitochondrial thiols and induces caspase-dependent apoptosis in human myeloid leukemia cells. Cell Death Dis (2013) 0.80

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer (2013) 0.80

Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate-resistant chronic myeloid leukemia patient. Oncol Lett (2013) 0.80

Hepatic manifestations in hematological disorders. Int J Hepatol (2013) 0.79

Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proc Natl Acad Sci U S A (2008) 0.79

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid (2010) 0.79

Hypersensitivity reaction to a mosquito bite in a patient with chronic myeloid leukemia. Case Rep Emerg Med (2011) 0.79

Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer (2014) 0.78

The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia. J Immunol Res (2015) 0.78

Solution structure and backbone dynamics of the AF-6 PDZ domain/Bcr peptide complex. Protein Sci (2007) 0.78

Alternative splicing of apoptosis-related genes in imatinib-treated K562 cells identified by exon array analysis. Int J Mol Med (2011) 0.78

The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. PLoS Genet (2015) 0.78

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol (2011) 0.78

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma (2010) 0.78

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. Oncotarget (2016) 0.78

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Rev Bras Hematol Hemoter (2012) 0.78

Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients. Int J Oncol (2016) 0.77

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet (2009) 0.77

FZD7 regulates BMSCs-mediated protection of CML cells. Oncotarget (2016) 0.77

Chronic Myeloid Leukaemia in The 21st Century. Ulster Med J (2007) 0.77

Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy. Vet Clin Pathol (2013) 0.76

Articles by these authors

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97

Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem (1999) 3.95

Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J (1998) 3.63

Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med (1997) 3.62

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood (1997) 3.14

The mortality of elder mistreatment. JAMA (1998) 3.11

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06

The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia (2012) 2.80

Analysis of environmental determinants of aggression and disruption in mentally retarded children. Appl Res Ment Retard (1986) 2.80

Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78

New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol (1999) 2.76

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66

Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol (2000) 2.61

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med (2001) 2.60

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53

Risk factors for reported elder abuse and neglect: a nine-year observational cohort study. Gerontologist (1997) 2.41

Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38

Effectiveness of brief time-out with and without contingent delay: a comparative analysis. J Appl Behav Anal (1986) 2.36

The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Proc Natl Acad Sci U S A (1996) 2.32

Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ (2001) 2.23

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21

Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 2.14

Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09

Thallium-201 single-photon emission CT versus CT for the detection of recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol (1999) 2.06

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma (2002) 2.04

Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma (1994) 2.04

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood (1999) 1.99

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96

Three-dimensional binary superlattices of magnetic nanocrystals and semiconductor quantum dots. Nature (2003) 1.94

ERV3, a full-length human endogenous provirus: chromosomal localization and evolutionary relationships. Virology (1984) 1.92

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90

Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88

Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999) 1.87

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol (1994) 1.85

Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med (1991) 1.82

Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS (1998) 1.74

Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction (2004) 1.74

Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71

Treatment of myelogenous leukemia: current status and investigational options. Blood (1996) 1.70

Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69

Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63

Helix handedness of Leptospira interrogans as determined by scanning electron microscopy. J Bacteriol (1979) 1.63

Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62

Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62

A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61

Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57

Emergency medicine resident work productivity in an academic emergency department. Acad Emerg Med (2000) 1.57

Movement of antibody-coated latex beads attached to the spirochete Leptospira interrogans. Proc Natl Acad Sci U S A (1981) 1.56

Structure, tissue distribution and genomic organization of the murine RRM-type RNA binding proteins TIA-1 and TIAR. Nucleic Acids Res (1996) 1.56

Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood (1999) 1.55

Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia (1995) 1.55

Physiology and pathophysiology of dendritic cells. Hum Pathol (1997) 1.54

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54

Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia (2008) 1.53

The use of a posterior lip augmentation device for a revision of recurrent dislocation after primary cemented Charnley/Charnley Elite total hip replacement: results at a mean follow-up of six years and nine months. J Bone Joint Surg Br (2007) 1.52

Management of hospital outbreaks of gastro-enteritis due to small roundstructured viruses. J Hosp Infect (2000) 1.52

Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52

Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood (2000) 1.52

2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51

Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res (2001) 1.51

Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49

Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol (1993) 1.49

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia (2012) 1.49

Septic arthritis after arthroscopic anterior cruciate ligament reconstruction. Diagnosis and management. Am J Sports Med (1997) 1.49